<DOC>
	<DOCNO>NCT02637141</DOCNO>
	<brief_summary>Protocol CELIM-NRCD-001 design Phase 2a , randomize , double-blind , placebo-controlled , parallel-group study evaluate efficacy safety AMG 714 attenuation effect gluten exposure adult patient celiac disease gluten challenge .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety AMG 714 Adult Patients With Celiac Disease</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Diagnosis celiac disease intestinal biopsy least 12 month prior screen On glutenfree diet least 12 month Negative celiac serology Avoidance pregnancy Severe complication celiac disease , refractory celiac disease Celiac symptoms Other concomitant autoimmune disease Chronic , active GI disease Infections , concomitant disease Prohibited medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>celiac</keyword>
	<keyword>gluten</keyword>
	<keyword>IL-15</keyword>
	<keyword>AMG 714</keyword>
</DOC>